½ÃÀ庸°í¼­
»óǰÄÚµå
1775461

¼¼°èÀÇ ½ÇÇè±â±¸ ½ÃÀå ¿¹Ãø(2025-2030³â)

Lab Equipment Market - Forecasts from 2025 to 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Knowledge Sourcing Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 150 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

½ÇÇè±â±¸ ½ÃÀåÀº CAGR 6.96%·Î 2025³â 195¾ï 700¸¸ ´Þ·¯¿¡¼­ 2030³â¿¡´Â 273¾ï 1,000¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

ÀǾàǰ R&D ÅõÀÚ Áõ°¡

Á¦¾à ȸ»ç´Â ¸¸¼º ÁúȯÀ» ÇØ°áÇϱâ À§ÇØ ¿¬±¸ °³¹ß ÅõÀÚ¸¦ ´ëÆø ´Ã¸®°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÇÇè±â±¸ ½ÃÀå¿¡ »ó´çÇÑ ±âȸ¸¦ âÃâÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2023³â¿¡ À¯·´ ÀǾàû(European Medicines Agency)Àº À¯ÀüÀÚ ¹× ¼¼Æ÷ Ä¡·á ½ÃÇèÀÇ ½ÂÀÎ ±â°£À» 25-30ÀÏ ´ÜÃàÇÏ´Â ½Å¼Ó ó¸® Á¦µµ¸¦ µµÀÔÇÏ¿© ±â¾÷µéÀÌ ÀǾàǰ °³¹ßÀ» ¿ì¼±ÀûÀ¸·Î ÁøÇàÇÒ ¼ö ÀÖµµ·Ï Çß½À´Ï´Ù. ÀÌ·¯ÇÑ ¿¬±¸ °³¹ß Ȱµ¿ÀÇ °­È­´Â ÀǾàǰ ¹ß°ß ¹× ½ÃÇè¿¡ ÇʼöÀûÀÎ ºÐ±¤°è, È¥ÇÕ±â, Àüµµµµ ÃøÁ¤±â µî ÷´Ü ½ÇÇè±â±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÕ´Ï´Ù.

¸¸¼º ÁúȯÀÇ À¯º´·ü »ó½Â

¾Ï, ´ç´¢º´, ½ÉÇ÷°ü Áúȯ µî ¸¸¼º ÁúȯÀÇ ºÎ´ãÀÌ Áõ°¡Çϰí ÀÖ´Â °ÍÀº ½ÃÀå ¼ºÀåÀÇ ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ¹Ì±¹ º¸°Çº¹ÁöºÎ(U.S. Department of Health and Human Services)¿¡ µû¸£¸é 2024³â ¹Ì±¹¿¡¼­ 190¸¸ °Ç ÀÌ»óÀÇ »õ·Î¿î ¾Ï »ç·Ê°¡ Áø´ÜµÇ¾úÀ¸¸ç, ¾à 61¸¸ ¸íÀÌ »ç¸ÁÇØ »ç¸Á ¿øÀÎ 2À§¸¦ Â÷ÁöÇß½À´Ï´Ù. ¶ÇÇÑ, ¾à 3,800¸¸ ¸íÀÇ ¹Ì±¹ÀÎÀÌ ´ç´¢º´À» ¾Î°í ÀÖÀ¸¸ç, ÀÌ´Â ½ÉÀ庴 ¹× ½ÅºÎÀü À§ÇèÀ» ³ôÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ÁúȯÀº ÷´Ü Áø´Ü ¹× ÀǾàǰ °³¹ßÀ» ÇÊ¿ä·Î Çϸç, È¿°úÀûÀÎ Ä¡·á¹ý ¿¬±¸¸¦ Áö¿øÇϱâ À§ÇÑ ½ÇÇè±â±¸¿¡ ´ëÇÑ ¼ö¿ä¸¦ Áõ°¡½Ã۰í ÀÖ½À´Ï´Ù. ƯÈ÷ °í·ÉÈ­ Àα¸¿¡¼­ ¼¼°èÀûÀ¸·Î ¸¸¼º ÁúȯÀÌ Áõ°¡ÇÔ¿¡ µû¶ó Ãֽűâ¼ú ½ÇÇè±â±¸ÀÇ Çʿ伺ÀÌ ´õ¿í Ä¿Áö°í ÀÖ½À´Ï´Ù.

»ý¹°ÇÐÀû Á¦Á¦ ¼ö¿ä Áõ°¡

»ý¹°ÇÐÀû Á¦Á¦(»ý¹°Ã¼¿¡¼­ ÃßÃâÇÑ ÀǾàǰ)ÀÇ ÀαⰡ ³ô¾ÆÁö¸é¼­ ½ÃÀå ¼ºÀå¿¡ Å©°Ô ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¼¼°èº¸°Ç±â±¸(WHO)ÀÇ ±¹Á¦ ÀÓ»ó µî·Ï Ç÷§Æû¿¡ µû¸£¸é, 2024³â¿¡´Â »ý¹°ÇÐÀû Á¦Á¦°¡ ÀǾàǰ ÆÄÀÌÇÁ¶óÀÎÀÇ »ó´ç ºÎºÐÀ» Â÷ÁöÇÒ °ÍÀ̸ç, ¼¼°èÀÇ ÀÓ»ó ½ÃÇèÀÇ 40%°¡ ÀÌ·¯ÇÑ Ä¡·á¹ý¿¡ ÁýÁßµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. »ý¹°ÇÐÀû Á¦Á¦´Â ¾Ï ¹× ÀÚ°¡ ¸é¿ª Áúȯ°ú °°Àº ÈçÇÑ Áúº´À» Ä¡·áÇϱâ À§ÇØ °³¹ß ¹× Å×½ºÆ®¿¡ Ư¼öÇÑ ½ÇÇè±â±¸°¡ ÇÊ¿äÇÕ´Ï´Ù. È¿´É°ú ¼ÒºñÀÚ ¼ö¿äÀÇ Áõ°¡¿¡ ÃËÁøµÈ »ý¹°ÇÐÀû Á¦Á¦ ¿¬±¸ÀÇ ±ÞÁõÀº ÷´Ü ½ÇÇè±â±¸ÀÇ Çʿ伺À» ÃËÁøÇÏ¿© ½ÃÀå È®ÀåÀ» ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

À¯Çüº°

½ÇÇè±â±¸ ½ÃÀåÀº ½Ã·á Ư¼º °¨Áö ±â´É(ºÐ±¤°è, Àüµµµµ°è µî)ÀÌ ÀÖ´Â Àåºñ¿Í ½Ã·á Ư¼º °¨Áö ±â´ÉÀÌ ¾ø´Â Àåºñ(¹Í¼­, ¿ë±¤·Î µî)·Î ±¸ºÐµË´Ï´Ù. °¨Áö ºÎ¹®Àº ƯÈ÷ »ý¹°ÇÐÀû Á¦Á¦ ¹× ¸¸¼º Áúȯ ¿¬±¸¿¡¼­ Á¤¹ÐÇÑ Áø´Ü ¹× ÀǾàǰ °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» Çϱ⠶§¹®¿¡ ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚº°

½ÃÀåÀº Á¤ºÎ, ¹ÙÀÌ¿À Á¦¾à, »ê¾÷ ¹× ±âŸ ÃÖÁ¾ »ç¿ëÀÚ·Î ºÐ·ùµË´Ï´Ù. ¹ÙÀÌ¿À Á¦¾à ºÎ¹®Àº ¸·´ëÇÑ R&D ÅõÀÚ¿Í ½Å¾à °³¹ß¿¡ ÇÊ¿äÇÑ Æ¯¼ö ÀåºñÀÇ ¼ö¿ä¿¡ ÈûÀÔ¾î 2024³â¿¡ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. Á¤ºÎ ¹× Çмú ¿¬±¸ ±â°üµµ °Ç°­ ¿¬±¸¿¡ ´ëÇÑ °ø°ø ÀÚ±ÝÀÇ Áö¿øÀ» ¹Þ¾Æ Áß¿äÇÑ ±â¿©¸¦ Çϰí ÀÖ½À´Ï´Ù.

Áö¿ªÀû ÅëÂû·Â

ºÏ¹Ì´Â ÷´Ü ÀÇ·á ÀÎÇÁ¶ó¿Í ¹Ì±¹¿¡ ÁÖ¿ä ¹ÙÀÌ¿À Á¦¾à ȸ»ç°¡ À§Ä¡ÇØ ÀÖ¾î »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. 2024³â¿¡´Â °­·ÂÇÑ R&D »ýŰèÀÇ Áö¿ø¿¡ ÈûÀÔ¾î ¼¼°èÀÇ ½ÇÇè±â±¸ ¸ÅÃâÀÇ 35% ÀÌ»óÀ» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´Àº Çõ½ÅÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ±ÔÁ¦ Áö¿ø¿¡ ÈûÀÔ¾î °­·ÂÇÑ ¼ºÀåÀ» º¸ÀÌ¸ç ±× µÚ¸¦ µû¸£°í ÀÖ½À´Ï´Ù.

°æÀï ÅëÂû·Â

Eppendorf AG, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc. ¹× Thermo Fisher Scientific Inc.¸¦ ºñ·ÔÇÑ ÁÖ¿ä ¾÷üµéÀº °­·ÂÇÑ ºê·£µå ¸í¼º°ú Çõ½ÅÀûÀÎ Á¦Ç°À¸·Î ½ÃÀåÀ» Áö¹èÇϰí ÀÖ½À´Ï´Ù. 2023³â¿¡ Thermo Fisher´Â »ý¹°ÇÐÀû Á¦Á¦ ¿¬±¸¿¡ ÀûÇÕÇÑ Ã·´Ü ºÐ±¤ ºÐ¼® Àåºñ¸¦ Ãâ½ÃÇÏ¿© ÀǾàǰ °³¹ßÀÇ Á¤¹Ðµµ¸¦ ³ô¿´½À´Ï´Ù.

½ÃÀåÀÇ °úÁ¦

°í±Þ ½ÇÇè±â±¸ÀÇ ³ôÀº ºñ¿ë°ú º¹ÀâÇÑ ½Ã½ºÅÛÀ» ¿î¿µÇϱâ À§ÇÑ ¼÷·ÃµÈ Àη ºÎÁ·Àº ƯÈ÷ °³¹ßµµ»ó±¹¿¡¼­ ÁÖ¿ä µµÀü °úÁ¦ÀÔ´Ï´Ù. ¶ÇÇÑ ÀÓ»ó ½ÃÇè¿¡ »ç¿ëµÇ´Â Àåºñ¿¡ ´ëÇÑ ¾ö°ÝÇÑ ±ÔÁ¦ ¿ä°ÇÀº ½ÃÀå ÁøÀÔÀ» Áö¿¬½Ãų ¼ö ÀÖÀ¸¸ç, Áؼö ±âÁØÀ» ÃæÁ·Çϱâ À§ÇØ Áö¼ÓÀûÀÎ Çõ½ÅÀÌ ÇÊ¿äÇÕ´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä ÀÌÁ¡

  • ÅëÂû·Â ÀÖ´Â ºÐ¼® : °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦Àû ¿äÀÎ, ¼ÒºñÀÚ ¼±È£µµ, »ê¾÷ ºÐ¾ß ¹× ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÃÊÁ¡À» ¸ÂÃç ÁÖ¿ä Áö¿ª°ú ½ÅÈï Áö¿ªÀ» Æ÷°ýÇÏ´Â ÀÚ¼¼ÇÑ ½ÃÀå ÅëÂû·ÂÀ» È®º¸ÇϽʽÿÀ.
  • °æÀï ȯ°æ : ¼¼°èÀÇ ÁÖ¿ä ¾÷üµéÀÌ Ã¤ÅÃÇÑ Àü·«Àû ¿òÁ÷ÀÓÀ» ÆÄ¾ÇÇÏ¿© ¿Ã¹Ù¸¥ Àü·«À¸·Î °¡´ÉÇÑ ½ÃÀå ħÅõ¸¦ ÀÌÇØÇϽʽÿÀ.
  • ½ÃÀå ÃËÁø¿äÀÎ ¹× ¹Ì·¡ µ¿Çâ : ¿ªµ¿ÀûÀÎ ¿äÀΰú Áß¿äÇÑ ½ÃÀå µ¿ÇâÀ» ޱ¸Çϰí, ÀÌ·¯ÇÑ ¿äÀÎÀÌ ¹Ì·¡ÀÇ ½ÃÀå ¹ßÀü¿¡ ¾î¶² ¿µÇâÀ» ¹ÌÄ¥Áö ÆÄ¾ÇÇÕ´Ï´Ù.
  • ½ÇÇà °¡´ÉÇÑ ±ÇÀå »çÇ× : ÅëÂû·ÂÀ» Ȱ¿ëÇÏ¿© Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®°í, ¿ªµ¿ÀûÀΠȯ°æ¿¡¼­ »õ·Î¿î ºñÁî´Ï½º È帧°ú ¼öÀÍÀ» âÃâÇϽʽÿÀ.
  • ±¤¹üÀ§ÇÑ °í°´Ãþ¿¡ ÀûÇÕ : ½Å»ý ±â¾÷, ¿¬±¸ ±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷ ¹× ´ë±â¾÷¿¡ À¯¿ëÇÏ°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù.

¾î¶² ¿ëµµ·Î »ç¿ëµË´Ï±î?

¾÷°è¿Í ½ÃÀå ÅëÂû·Â, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¿ªÀû È®´ë, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©°ú ¿µÇâ, ½ÅÁ¦Ç° °³Ã´, °æÀïÀÇ ¿µÇâ

Á¶»ç ¹üÀ§

  • ½ÇÀû Å×ÀÌÅÍ(2022-2024³â) ¹× ¿¹Ãø µ¥ÀÌÅÍ(2025-2030³â)
  • ¼ºÀå ±âȸ, °úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ Ʋ, µ¿Ç⠺м®
  • °æÀï Æ÷Áö¼Å´×, Àü·«, ½ÃÀå Á¡À¯À² ºÐ¼®
  • ¼öÀÍÀÇ ¼ºÀå°ú ¿¹Ãø °¢±¹À» Æ÷ÇÔÇÑ ºÎ¹®¿Í Áö¿ªÀÇ ºÐ¼®
  • ±â¾÷ ÇÁ·ÎÆÄÀϸµ(Àü·«, Á¦Ç°, À繫 »óȲ, ÁÖ¿ä ¹ßÀü µî)

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå ÇöȲ

  • ½ÃÀå °³¿ä
  • ½ÃÀåÀÇ Á¤ÀÇ
  • Á¶»ç ¹üÀ§
  • ½ÃÀå ¼¼ºÐÈ­

Á¦3Àå ºñÁî´Ï½º »óȲ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ½ÃÀå ±âȸ
  • Porter's Five Forces ºÐ¼®
  • ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
  • Á¤Ã¥ ¹× ±ÔÁ¤
  • Àü·«Àû Á¦¾È

Á¦4Àå ±â¼ú Àü¸Á

Á¦5Àå ¼¼°èÀÇ ½ÇÇè±â±¸ ½ÃÀå : À¯Çüº°

  • ¼Ò°³
  • ºÐ¼®±â±â
  • ÀϹÝÀûÀÎ ½ÇÇè±â±¸
  • ÃøÁ¤ ¹× ¸ð´ÏÅ͸µ Àåºñ
  • Ư¼ö Àåºñ
  • Áö¿ø Àåºñ

Á¦6Àå ¼¼°èÀÇ ½ÇÇè±â±¸ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • Çмú±â°ü ¹× ¿¬±¸±â°ü
  • ¹ÙÀÌ¿ÀÀǾàǰ ¹× Á¦¾àȸ»ç
  • ÀÇ·á ¹× Áø´Ü½ÇÇè½Ç
  • Á¤ºÎ ¹× ±ÔÁ¦ ±â°ü
  • »ê¾÷ ¹× Á¦Á¶¾÷
  • ±âŸ

Á¦7Àå ¼¼°èÀÇ ½ÇÇè±â±¸ ½ÃÀå : Áö¿ªº°

  • ¼Ò°³
  • ºÏ¹Ì
    • À¯Çüº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
      • ¹Ì±¹
      • ij³ª´Ù
      • ¸ß½ÃÄÚ
  • ³²¹Ì
    • À¯Çüº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
      • ºê¶óÁú
      • ¾Æ¸£ÇîÆ¼³ª
      • ±âŸ
  • À¯·´
    • À¯Çüº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
      • ¿µ±¹
      • µ¶ÀÏ
      • ÇÁ¶û½º
      • ½ºÆäÀÎ
      • ±âŸ
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • À¯Çüº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
      • »ç¿ìµð¾Æ¶óºñ¾Æ
      • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
      • ±âŸ
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • À¯Çüº°
    • ÃÖÁ¾ »ç¿ëÀÚº°
    • ±¹°¡º°
      • Áß±¹
      • ÀϺ»
      • Àεµ
      • Çѱ¹
      • ´ë¸¸
      • ±âŸ

Á¦8Àå °æÀï ȯ°æ°ú ºÐ¼®

  • ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
  • ½ÃÀå Á¡À¯À² ºÐ¼®
  • ÇÕº´, Àμö, ÇÕÀÇ, Äݶ󺸷¹À̼Ç
  • °æÀï ´ë½Ãº¸µå

Á¦9Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Eppendorf AG
  • Beckman Coulter, Inc.
  • Agilent Technologies, Inc.
  • Thermo Fisher Scientific Inc.
  • Waters Corporation
  • F. Hoffmann-La Roche Ltd
  • Shimadzu Corporation
  • Bio-Rad Laboratories, Inc.
  • PerkinElmer Inc.

Á¦10Àå ºÎ·Ï

  • ÅëÈ­
  • ÀüÁ¦Á¶°Ç
  • ±âÁØ¿¬µµ ¹× ¿¹Ãø¿¬µµÀÇ Å¸ÀÓ¶óÀÎ
  • ÀÌÇØ °ü°èÀÚ¿¡°Ô À־ÀÇ ÁÖ¿ä ÀÌÁ¡
  • Á¶»ç ¹æ¹ý
  • ¾à¾î
HBR

The Lab Equipment Market is expected to grow from USD 19.507 billion in 2025 to USD 27.310 billion in 2030, at a CAGR of 6.96%.

Increasing Investments in Pharmaceutical R&D

Pharmaceutical companies are significantly boosting R&D investments to address chronic diseases, creating substantial opportunities for the lab equipment market. In 2024, global pharmaceutical R&D spending reached USD 280 billion, with a focus on developing innovative drugs and biologics, according to industry reports. Government initiatives are further accelerating this trend by streamlining clinical trial processes. For instance, in 2023, the European Medicines Agency introduced fast-track schemes reducing approval times for gene and cell therapy trials by 25-30 days, enabling companies to prioritize drug development. This heightened R&D activity drives demand for advanced lab equipment, such as spectrometers, mixers, and conductivity meters, essential for drug discovery and testing.

Rising Prevalence of Chronic Diseases

The growing burden of chronic diseases, including cancer, diabetes, and cardiovascular conditions, is a key driver of market growth. In the United States, over 1.9 million new cancer cases were diagnosed in 2024, with approximately 610,000 deaths, making it the second leading cause of mortality, per the U.S. Department of Health and Human Services. Additionally, around 38 million Americans live with diabetes, increasing risks of heart disease and kidney failure. These conditions necessitate advanced diagnostics and drug development, boosting demand for lab equipment to support research into effective treatments. The global rise in chronic diseases, particularly in aging populations, further amplifies the need for cutting-edge laboratory tools.

Growing Demand for Biologics

The increasing popularity of biologics-drugs derived from living organisms-is significantly contributing to market growth. In 2024, biologics accounted for a substantial portion of the pharmaceutical pipeline, with 40% of clinical trials globally focused on these therapies, according to the World Health Organization's International Clinical Registry Platform. Biologics target prevalent diseases like cancer and autoimmune disorders, requiring specialized lab equipment for development and testing. This surge in biologics research, driven by their efficacy and growing consumer demand, is propelling the need for advanced laboratory tools, further fueling market expansion.

Market Segmentation Analysis

By Type

The lab equipment market is segmented into equipment with sample characteristic sensing (e.g., spectrometers, conductivity meters) and without sample characteristic sensing (e.g., mixers, furnaces). The sensing segment dominates due to its critical role in precise diagnostics and drug development, particularly for biologics and chronic disease research.

By End-User

The market is classified into government, biopharmaceutical, industrial, and other end-users. The biopharmaceutical segment held the largest share in 2024, driven by heavy R&D investments and the need for specialized equipment in drug discovery. Government and academic research institutions are also significant contributors, supported by public funding for health research.

Geographical Insights

North America holds a significant market share, driven by advanced healthcare infrastructure and the presence of major biopharmaceutical companies in the U.S. In 2024, the region accounted for over 35% of global lab equipment revenue, bolstered by robust R&D ecosystems. The Asia-Pacific region is the fastest-growing, fueled by rising chronic disease prevalence and increasing pharmaceutical investments in countries like China and India. For instance, India's 2024 healthcare budget allocated USD 15 billion for R&D, enhancing lab equipment demand. Europe follows, with strong growth driven by regulatory support for innovative therapies.

Competitive Insights

Key players, including Eppendorf AG, F. Hoffmann-La Roche Ltd, Agilent Technologies, Inc., and Thermo Fisher Scientific Inc., dominate the market due to their strong brand reputation and innovative product offerings. In 2023, Thermo Fisher launched advanced spectrometry equipment tailored for biologics research, enhancing precision in drug development. Agilent introduced automated lab solutions in 2024, improving efficiency in high-throughput testing. These companies are leveraging strategic acquisitions and R&D investments to maintain market leadership.

Market Challenges

High costs of advanced lab equipment and the need for skilled personnel to operate complex systems pose challenges, particularly in developing regions. Additionally, stringent regulatory requirements for equipment used in clinical trials can delay market entry, requiring continuous innovation to meet compliance standards.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2022 to 2024 & forecast data from 2025 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Lab Equipment Market Segmentation

By Type

  • Analytical Instruments
  • General Lab Equipment
  • Measuring & Monitoring Devices
  • Specialty Equipment
  • Support Equipment

By End-User

  • Academic & Research Institutes
  • Biopharmaceutical & Pharmaceutical Companies
  • Healthcare & Diagnostic Labs
  • Government & Regulatory Bodies
  • Industrial & Manufacturing
  • Others

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • Israel
  • Others
  • Asia Pacific
  • China
  • Japan
  • South Korea
  • India
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. GLOBAL LAB EQUIPMENT MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Analytical Instruments
  • 5.3. General Lab Equipment
  • 5.4. Measuring & Monitoring Devices
  • 5.5. Specialty Equipment
  • 5.6. Support Equipment

6. GLOBAL LAB EQUIPMENT MARKET BY END-USER

  • 6.1. Introduction
  • 6.2. Academic & Research Institutes
  • 6.3. Biopharmaceutical & Pharmaceutical Companies
  • 6.4. Healthcare & Diagnostic Labs
  • 6.5. Government & Regulatory Bodies
  • 6.6. Industrial & Manufacturing
  • 6.7. Others

7. GLOBAL LAB EQUIPMENT MARKET BY GEOGRAPHY

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. By Type
    • 7.2.2. By End-User
    • 7.2.3. By Country
      • 7.2.3.1. USA
      • 7.2.3.2. Canada
      • 7.2.3.3. Mexico
  • 7.3. South America
    • 7.3.1. By Type
    • 7.3.2. By End-User
    • 7.3.3. By Country
      • 7.3.3.1. Brazil
      • 7.3.3.2. Argentina
      • 7.3.3.3. Others
  • 7.4. Europe
    • 7.4.1. By Type
    • 7.4.2. By End-User
    • 7.4.3. By Country
      • 7.4.3.1. United Kingdom
      • 7.4.3.2. Germany
      • 7.4.3.3. France
      • 7.4.3.4. Spain
      • 7.4.3.5. Others
  • 7.5. Middle East and Africa
    • 7.5.1. By Type
    • 7.5.2. By End-User
    • 7.5.3. By Country
      • 7.5.3.1. Saudi Arabia
      • 7.5.3.2. UAE
      • 7.5.3.3. Others
  • 7.6. Asia Pacific
    • 7.6.1. By Type
    • 7.6.2. By End-User
    • 7.6.3. By Country
      • 7.6.3.1. China
      • 7.6.3.2. Japan
      • 7.6.3.3. India
      • 7.6.3.4. South Korea
      • 7.6.3.5. Taiwan
      • 7.6.3.6. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Market Share Analysis
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Competitive Dashboard

9. COMPANY PROFILES

  • 9.1. Eppendorf AG
  • 9.2. Beckman Coulter, Inc.
  • 9.3. Agilent Technologies, Inc.
  • 9.4. Thermo Fisher Scientific Inc.
  • 9.5. Waters Corporation
  • 9.6. F. Hoffmann-La Roche Ltd
  • 9.7. Shimadzu Corporation
  • 9.8. Bio-Rad Laboratories, Inc.
  • 9.9. PerkinElmer Inc.

10. APPENDIX

  • 10.1. Currency
  • 10.2. Assumptions
  • 10.3. Base and Forecast Years Timeline
  • 10.4. Key benefits for the stakeholders
  • 10.5. Research Methodology
  • 10.6. Abbreviations
»ùÇà ¿äû ¸ñ·Ï
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
¸ñ·Ï º¸±â
Àüü»èÁ¦